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Case presentation 
A 23-year-old man developed end-stage renal failure second- 
ary to  us glomerulonephrfitis. systemic lupus erythematosus 
(SLE) was diagnosed 4.5 years ago on the basis of typical clinical 
and laboratory findings. His renal function was initially normal, 
but 6 months later moderate renal insufficiency was noted when 
he was hospitalized for severe hypertension and cardiac failure. 
A Scribner shunt was placed to permit management of fluid over- 
load by dialysis, but the shunt could not be preserved because a 
Staphylococcus aureus infection developed at  the shunt site. 
Renal biopsy revealed severe, diffuse proliferative glomerulone- 
phritis consistent with lupus. The patient was treated initially 
with high doses of prednisone and with diazoxide, propranolol, 
furosemide, hydralazine, and methyldopa. His blood pressure 
was controlled on this regimen and his serum creatinine fell from 
5.0 mg/dl to approximately 3.8 mg/dl. The dose of prednisone 
was gradually reduced to 10 mg every other day. rreatment with 
large doses of propranolol, hydralazine, methyldlopa, thiazides, 
and furosemide failed to control his blood pressure over the next 
few months; his cardiomegaly progressed and cardiac failure 
worsened. 
Two and one-half years ago, minoxidil was added to his anti- 
hypertensive regimen, and his diastolic blood pressure was re- 
duced to between 100 and 110 mg Hg; his renal function deterio- 
rated, however. The addition of cyclophosphamide to the regi- 
men stabilized his renal function at a serum creatinine of 
approximately 4.5 mg/dl. The cyclophosphamide was discontin- 
ued 1.5 years ago, however, because the patient developed pan- 
cytopenia; the serum creatinine, which had increased to approxi- 
mately 5.5 mgidl after the drug was discontinued, temporarily 
stabilized at  this level. 
One year ago, during a hospitalization for pneumococcal 
pneumonia, the patient's renal function further declined; the 
serum creatinine rose to 8.5 mg/dl and the BUN increased 
to 150 mgidl. A pericardial effusion developed and failed to 
respond to daily hemodialysis (via a second Scribner shunt) 
using regional administration of heparin; the effusion increased 
in size, cardiac tamponade occurred, and pericardiocentesis 
was required. An anterior pericardiectomy was performed to 
avert recurrent tamponade. The pericardial fluid was grossly 
bloody (hematocrit 25'%) and did not contain autoantibodies. 
Pathologic examination revealed fibrinous pericarditis. At no 
time before or during the episode of pericarditis was any clinical 
or laboratory evidence of "active" SLE apparent. 
Following the patient's hospitalization for pericarditis, hemo- 
dialysis was complicated by recurrent problems of vascular ac- 
cess. The second Scribner shunt was removed because of another 
S. aureus infection, and a third shunt was inserted but functioned 
only transiently. An effort was made to convert this shunt to an 
arteriovenous fistula, but the fistula clotted before it could be 
used. A fourth shunt was inserted, but it too became a focus of 
staphylococcal infection and was removed. For one month fol- 
lowing removal of the fourth shunt, hemodialysis was performed 
every 5 days via a femoral vein catheter. During this difficult 
period, the patient's compliance with therapy was poor and his 
diastolic blood pressure remained at  100 to 110 mm Hg. 
Four months ago, a CortexB graft was interposed between the 
brachial artery and cephalic vein; since then the patient has been 
dialyzed twice weekly, and compliance with all aspects of thera- 
py has improved markedly. At present, he has no symptoms or 
signs of SLE or cardiac failure. 
His most recent physical examination showed mild facial puffi- 
ness and grade 2 hypertensive changes in the optic fundi. The 
point of maximal impulse was at the anterior axillary line in the 
7th intercostal space; a left ventricular heave was prominent. A 
systolic rub and S3 and S4 gallops were present. The chest was 
clear, and the patient had no jugular vein distention, hepatomeg- 
aly, or edema. The site of the cortexB graft in the left arm was 
well healed, was uninfected, and had a prominent thrill. No ar- 
thritis, rash, lymphadenopathy, or alopecia were present. 
The current medical regimen of minoxidil (40 mg/day), pro- 
pranolol (640 mg/day), and furosemide (320 mg/day), has main- 
tained the patient's blood pressure at 160180 to 1601100 mm Hg. 
The patient also takes digoxin, 0.125 mg, every other day, alumi- 
num hydroxide, folic acid, and multivitamins; the prednisone has 
been discontinued. He receives neither iron nor androgens. His 
daily urinary output is 500 to 800 cc. 
Predialysis values for BUN and serum creatinine are approxi- 
mately 130 mgidl and 13.0 mgidl respectively. The anti-DNA titer 
is normal and the serum complement mildly depressed. The he- 
matocrit is 20%. The patient has received a total of 27 trans- 
fusions, 12 since the initiation of hemodialysis. A chest x-ray and 
echocardiogram show marked left ventricular hypertrophy but 
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no pericardial fluid. He has returned to school to study electronic
repair and is currently considering renal transplantation.
Discussion
DR. J. MICHAEL LAZARUS (Nephrology Division,
Peter Bent Brigham Hospital, and Associate Pro-
fessor of Medicine, Harvard Medical School, Bos-
ton, Mass.): This patient with systemic lupus ery-
thematosus and renal failure has experienced mu!-
tiple complications including severe and persistent
hypertension, uncontrolled congestive heart failure,
pancytopenia and infection secondary to immuno-
suppressive therapy, multiple shunt failures with in-
fection, and pericarditis requiring pericardiectomy.
These sequelae are unusually severe but demon-
strate the typical complications experienced by pa-
tients undergoing chronic hemodialysis. In my opin-
ion, the difficulties encountered, save those due to
access failure, are not related to hemodialysis per
se, but rather to lupus erythematosus, persistent
uremia, and drug therapy.
In the subsequent discussion, I will divide com-
plications of hemodialysis into those that are (1)
consequences of the usual dialysis procedure; (2)
mechanical, iatrogenic, or both; and (3) manifesta-
tions of persistent or incompletely treated uremia.
Other treatment options such as peritoneal dialysis
and renal transplantation will not be discussed, but
obviously these play an important role in the man-
agement of complications associated with hemo-
dialysis.
Medical threapy has produced few treatments as
dramatically lifesaving as dialysis. Many physi-
cians, particularly nonnephrologists, aware only of
the dramatic and beneficial effects of dialysis, have
become nonchalant about hemodialysis. Like all
forms of therapy, hemodialysis is a double-edged
sword that can have severe, adverse consequences,
including death. Knowledge of the potential haz-
ards of treatment thus is mandatory to estimate ac-
curately the risks and benefits of hemodialysis.
Consequences of the usual hernodia[ysis procedure
Hemodialysis can be viewed as two distinct phe-
nomena: clearance and ultrafiltration. Conceptual
separation of clearance or diffusion and ultrafiltra-
tion is necessary for understanding the dialysis pro-
cedure and developing the proper approach to indi-
vidual patients. One can utilize a rapid blood flow
rate and large surface area dialyzer to increase or
maintain clearance, yet minimize fluid removal ei-
ther by using low hydrostatic pressure or replacing
a quantity of fluid equal to that removed. On the
other hand, one can minimize clearance utilizing a
small dialyzer with a slow blood flow rate while us-
ing maximum hydrostatic ultrafiltration to achieve
greater fluid removal.
Changes in vascular volume. The most critical
change that occurs with hemodialysis is reduction
of extracellular volume by ultrafiltration. I believe
that failure to control extracellular volume ade-
quately is the major long-term contributor to mor-
bidity and mortality in patients with end-stage renal
disease. Insidious visceral engorgement, third-
space collections, and pulmonary edema result
from fluid overload. Hypertension in dialysis pa-
tients is also usually volume dependent [1, 2], and
the high incidence of cardiovascular disease in ure-
mic patients largely results from the persistent fluid
overload and resulting hypertension [3]. Therefore,
efforts at reducing vascular volume to its lowest
possible point, i.e., "dry weight," are very impor-
tant in these patients.
Several factors influence the likelihood of compli-
cations during fluid removal by dialysis: (1) volume
of the dialyzer and blood lines; (2) compliance of
the dialyzer, that is, the degree of expansion of the
blood compartment with an increase in resistance to
flow; and (3) magnitude of ultrafiltration. A large ex-
tracorporeal circulation, a highly compliant dialy-
zer, and an increased ultrafiltration coefficient are
more likely to lead to hypotension than is a small
surface area dialyzer with a low ultrafiltration coef-
ficient. Newer dialyzing membranes allow a degree
of ultrafiltration such that fluid can be removed
from the vascular compartment faster than it can be
replenished from interstitial and intercellular
spaces. Other factors such as uremic autonomic
neuropathy [4, 51, hormonal changes, and myo-
cardial disease complicate efforts at reducing vascu-
lar volume. The potential adverse effects of anti-
hypertensive medications as well as changes in os-
molality and blood acetate concentration also
should be assessed when one attempts ultrafiltra-
tion.
Total separation of diffusion and ultrafiltration
does not occur in standard dialysis because blood
flow is necessary to generate venous pressure and
also because of the effect of ultrafiltration on con-
vective diffusion, i.e., the movement of solutes that
results from movement of the solvent. So called
"sequential dialysis" is a procedure in which ultra-
filtration and clearance are separated [6]. Ultrafil-
tration occurs across a high-flux dialysis membrane
without dialysis flow for short periods; then dialysis
is begun and clearance occurs, but no fluid removal
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is attempted. Recent investigations have indicated
that this separation of diffusion and ultrafiltration
might allow a more stable dialysis and facilitate the
removal of larger quantities of fluid [7]. Obviously,
reduction of extracellular volume below some criti-
cal point, regardless of technique, will lead to hypo-
tension and its consequences.
The benefits of fluid removal must be weighed
against the potential hazards. Extracting large
quantities of fluid in one treatment can lead to tran-
sient episodes of hypotension and severe cardiovas-
cular and cerebral sequelae. In the young, relatively
well, hypertensive patient, such as the patient pre-
sented today, one should be aggressive in removing
fluid; in the elderly patient with cerebrovascular or
cardiovascular disease, efforts at reaching the pa-
tient's dry weight must be tempered. It is important
that the physician encourage minimum weight gains
between treatments so that only small reductions in
volume will be necessary with each dialysis. Gener-
ally, if one can discontinue antihypertensive medi-
cations, blood pressure remains more stable during
dialysis and extracellular fluid is more easily re-
moved. Indeed, antihypertensive medication often
then becomes unnecessary. In the small percentage
of patients whose hypertension does not respond to
a reduction in extracellular volume, antihyperten-
sive medication must be continued, but drug thera-
py should be withheld for 4 to 6 hours preceding the
dialysis procedure so that the vasodilatory effect of
these drugs will be minimized during dialysis.
Electrolyte and osmolar shifts. Abrupt changes in
the concentration of sodium, potassium, and cal-
cium during hemodialysis can induce serious con-
sequences. Diffusion or clearance of electrolytes
and other substances can create changes in intra-
and extracellular concentrations and can alter os-
molality. The rate of diffusion or clearance depends
on the surface area of the dialyzer, characteristics
of the membrane, blood and dialysate flow rates,
and the concentration gradients between blood and
dialy sate.
Most dialysate solutions have sodium concentra-
tions between 130 and 140 mEq/liter. The lower so-
dium concentrations are used to remove sodium
and thereby reduce blood pressure. However, pa-
tients frequently develop mild hyponatremia, a
chemical disorder that might be related to the devel-
opment of side effects such as muscle cramps and
dialysis disequilibrium. Severe dialysis dis-
equilibrium is manifested by marked mental and
psychiatric changes and grand mal seizures; a mild
disequilibrium occurring after dialysis produces
headache, fatigue, and lethargy [8, 9]. Rapid
changes in the concentration of urea or other un-
identified osmotically active agents (idiogenic os-
moles) and changes in the pH of the central nervous
system contribute to the pathogenesis of this syn-
drome [9, 10]. The rate of change of serum sodium,
urea, or other substance is probably more important
than is the quantity of any substance removed. The
syndrome usually can be prevented by avoiding
prolonged and efficient dialysis, particularly when
the blood urea nitrogen is markedly elevated.
Gentle correction of the uremia can be accom-
plished by dialyzing for brief periods at first, main-
taining low blood flows, and using a dialyzer with a
small surface area. Of course, this approach results
in a slower resolution of the uremia and its atten-
dant complications. Intravenous osmotic agents
such as mannitol or dextrose reduce the intensity of
osmolar change and are believed by some to be ef-
fective in preventing muscle cramps and dis-
equilibrium [11]. Use of the ideal sodium concentra-
tion in the dialysate should strike a balance: it
should remove sodium while obviating symptoms of
hyponatremia.
The most critical electrolyte shift in patients un-
dergoing hemodialysis involves potassium. Hyper-
kalemia often occurs in patients with advanced re-
nal failure. One can lower serum potassium by uti-
lizing a dialysate potassium concentration between
1.5 and 3.0 mEq/liter. In the patient with cardiac
failure who takes digitalis, the patient with coronary
disease and an irritable conduction system, or the
small, elderly patient whose dietary intake is in-
adequate, a low potassium concentration in the
dialysate can lead to transient hypokalemia and se-
vere rhythm disturbances. Such patients require a
higher potassium concentration in the dialysate.
Dialysate potassium concentration can be manipu-
lated readily in the dialyzer assigned to a single pa-
tient. In central delivery systems, however, all pa-
tients undergo dialysis against a bath of the same
composition. To avoid hyperkalemia in many of the
patients dialyzed on a central system, one must use
a dialysate potassium concentration of 3 mEq/liter
or less. At these relatively low potassium concen-
trations, hypokalemia occurs transiently in some
patients, and arrhythmias can develop in the sus-
ceptible groups described before, but careful oral
administration of small quantities of potassium usu-
ally can solve this problem. A patient with an ex-
tremely high serum potassium level probably
should not be dialyzed initially against a very low
dialysate potassium concentration because, in my
786 Nephrology Forum
experience, abrupt and large changes in serum po-
tassium can induce cardiac rhythm disturbances. A
preferable approach to such a patient is multiple
bath changes with graded lowering of the potassium
concentration of the dialysate. Finally, we should
remember that serum calcium levels are altered by
dialysate calcium and that the relationship between
calcium and potassium as well as the absolute
serum levels of these electrolytes are important fac-
tors in cardiac activity [121.
Acetate accumulation. In the early 1960s, acetate
was developed as a dialysate buffer to avoid the use
of complicated systems containing bicarbonate and
bubbled carbon dioxide [13]. An acetate buffer can
cause transient decreases in serum bicarbonate,
however [14, 15]. Sargent and Gotch recently dem-
onstrated that patients treated for long periods with
acetate-buffered dialysate become bicarbonate de-
pleted [16]. In addition, transient acetate accumula-
tion occurs during and immediately after dialysis in
a significant percentage of patients [17, 18]. Al-
though the exact cause of this accumulation is un-
known, it might result from (1) administration of
acetate at a rate exceeding metabolic clearance; (2)
a reduction, because of circulatory insufficiency, of
acetate delivery to active metabolic sites; or (3) de-
fective acetate metabolism [18, 19]. The acetate ion
has been cited as a cause of myocardial depression
[20, 21] and cardiovascular instability in seriously ill
patients [22]. Simpler systems for the delivery of bi-
carbonate dialysate recently have been developed,
and investigation is underway to evaluate further
the benefits of bicarbonate as the source of alkali in
patients undergoing hemodialysis.
Anticoagulation. Abnormalities of platelet factor
III activity and platelet adhesiveness due to uremia
can be reversed by hemodialysis [23]. Bleeding re-
mains a risk, however, because systemic adminis-
tration of heparin is necessary in carrying out extra-
corporeal circulation. Also, many dialysis patients
are treated with warfarin, aspirin, and antiplatelet
drugs to help preserve the patency of arteriovenous
shunts and fistulas. These agents can induce a varie-
ty of bleeding complications including gastrointesti-
nal hemorrhage; bloody pericardial, pleural, and
joint effusion; subdural hematoma; retroperitoneal
hematoma; ocular and retinal hemorrhage; and in-
creased menstrual flow [24]. The use of invasive di-
agnostic and therapeutic procedures shortly before
or after hemodialysis has been associated with un-
usual hemorrhagic complications. If possible, such
procedures should be deferred until the effects of
heparin have dissipated.
Shunt and fistula problems. The most frequent
causes of hospitalization in patients on maintenance
hemodialysis are replacement, repair, removal, or
treatment of infection of an arteriovenous (AV)
shunt or fistula (Table 1). The AV shunt is now used
primarily when a patient is expected to require dial-
ysis for only days or a few weeks; the AV fistula,
created either from a native vein or with a prosthe-
sis, is usually reserved for long-term care. Although
AV shunts have a high incidence of thrombosis and
infection, they can be used immediately and do not
require venipuncture. The Seldinger technique of
percutaneous catheterization of major vessels, de-
scribed almost 20 years ago [25], recently has
gained renewed interest as a means of access for
hemodialysis. Femoral vein catheterization cur-
rently is used most frequently [26], but subclavian
vein catheterization also has been described [27].
We prefer vein catheterization rather than an A-V
shunt because it can be used immediately, preserves
arteries and veins, does not involve a surgical pro-
cedure, and is relatively safe. Complications, al-
though unusual, include retroperitoneal hematoma,
injuries to the adjacent artery with hemorrhage, and
infection if an unattended catheter is left in place
[28, 29]. Femoral vein catheterization is probably
the procedure of choice for patients with uncompli-
cated acute renal failure and can provide a tempo-
rary approach in patients on maintenance dialysis
who are awaiting a more permanent type of access.
An AV fistula created with the patient's own
blood vessels provides the most desirable access
and is least susceptible to infection and thrombosis
[30]. However, suitable fistulas cannot always be
created because of previous trauma to the venous
system from intravenous therapy or because of
compromised arterial flow. Prosthetic AV fistulas
can be used when native vessels are not suitable.
These implants produce thrombosis and infection
less often than does the AV shunt but more often
than the native vein fistula [30, 31]. The prosthetic
AV fistula can be easily placed even when native
vessels are not available. Because this situation
Table 1. Complications of shunts and fistulas
Repeated thromboses requiring multiple operations
Vascular compromise and vascular steal"
Infection
Local
Endarteritis with septicemia and septic emboli
Aneurysm with rupture
Increased cardiac output
Carpal tunnel syndrome
Recirculation yielding inadequate dialysis
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occurs often, the prosthetic AV fistula is the most
commonly used means of access to the circulation.
Access to the circulation is clearly the Achilles
heel of chronic hemodialysis; the patient described
today had four access operations before a success-
ful AV fistula could be created. Multiple surgical
procedures,. prolonged hospitalization, and deple-
tion of access sites cause much anxiety and stress in
hemodialysis patients. In some, particularly elderly
or diabetic patients with previously compromised
arterial flow, reduction of blood supply leads to tis-
sue ischemia and occasionally to amputation of a
digit or extremity. This problem is so severe in dia-
betic patients that many vascular surgeons avoid
placing a shunt or fistula in the leg. A less common
complication is the "steal syndrome," which oc-
curs when the distal radial artery has not been ligat-
ed and blood flows from the ulnar artery to the
palmar arch into the fistula [32]. Upper arm AV fis-
tulas also have been reported to cause the steal syn-
drome [33]. The AV shunt or fistula increases car-
diac output approximately 5% to 8%, and this effect
must be considered in patients who have borderline
cardiac function. The advantages of controlling
fluid volume and hypertension through hemo-
dialysis usually outweigh the disadvantages of in-
creased cardiac output.
Recirculation is the phenomenon of an in-
appropriate mixture of venous and arterial blood in
the fistula, such that a "short circuit" occurs in the
systemic circulation. Recirculation results when a
single needle is used or when two needles are
placed close together in a fistula that has a high
pressure due to resistance to outflow. The degree of
recirculation can be calculated by determining the
BUN or serum creatinine from specimens taken si-
multaneously from the arterial line (A), venous line
(V), and a distant peripheral source (P):
P—A
—
x 100 = % recirculation
Generally, a good fistula with proper cannulation
has a recirculation of less than approximately 10%.
Infection is a common and serious complication
in the patient with a shunt or fistula. The most com-
mon type of infection is confined to the access site,
but some patients develop infective endarteritis
with septicemia and septic emboli. Staphylococcus
aureus is the most common pathogen [30, 34]. Orga-
nisms presumably gain access to the circulation ei-
ther from local infections or as a consequence of
manipulation of the fistula or shunt in conjunction
with dialysis. Endarteritis in dialysis is manifested
by fever, and peripheral emboli; the patient's
blood cultures are positive. Endarteritis mimics
bacterial endocarditis, which also can result from
infection of the access site. A changing heart
murmur or other evidence of valve involvement,
e.g., an abnormal echocardiogram, is sometimes
the only clue for differentiating endocarditis from
endarteritis. If treated early and vigorously, the
prognosis of septicemia associated with fistulas and
shunts is favorable [30, 34]. Treatment should be
given for at least one week for local infections and
for as long as two months for septicemia, septic em-
boli, or endocarditis. When septicemia persists, re-
moval of the prosthesis might become necessary.
The use of newer prosthetic materials such as poly-
tetrafluoroethylene initially seemed to offer de-
creased rates of infection [35]; however, our experi-
ence indicates that thrombosis and infection are
continuing problems [36].
It is extremely important that a native vein fistula
be created before the patient becomes overtly ure-
mic and before the veins are repeatedly traumatized
by venipuncture or intravenous infusions. In the pa-
tient with progressive renal failure, the surgical pro-
cedure should be performed when the serum creati-
nine reaches 6 to 8 mgldl so that the fistula will have
sufficient time to enlarge before it is needed. Simi-
larly, early placement of a prosthetic fistula is also
important in allowing time for full healing and reso-
lution of edema before use. In my experience, early
placement is the most important factor in achieving
prolonged survival of fistulas, and it probably would
have avoided some of the access problems in the
patient presented.
Mechanical and iatrogenic complications of
hemodialysis
Complications that can result from equipment
failure or errors by physicians and nurses are listed
in Table 2. Air embolus and the consequences of
improper composition of the dialysate (e.g., hemol-
ysis and extreme changes in tonicity) were devas-
tating complications in the past, but improved auto-
mated equipment and safety features largely elimi-
nated these problems. Hemolysis can occur from
inadequate water treatment or contamination of the
dialysate [37, 38]. Other clinical problems such as
dementia, hypertension, and sudden death can re-
sult from dialysate contamination with substances
such as aluminum, calcium, and fluoride. Con-
tamination can be prevented by the use of a deion-
izer, a reverse-osmosis device, or both [39—41].
Toxic chemicals such as diethylthalate and poly-
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Table 2. Mechanical and iatrogenic complications of
hemodialysis
Air embolus
Acute hemorrhage
Dialyzer leak
Disconnected shunt
Acute rupture of fistula (aneurysm)
Hemolysis
Dilute dialysate
Copper contamination
Chloramine, nitrate, formaldehyde contamination
Overheated dialysate
Acute hypernatremia
Contaminated dialysate
Bacterial
Trace elements or compounds in untreated water
Fluoride
Calcium
Magnesium
Insecticides
Aluminum
Synthetic material intoxication
Membrane-mediated pulmonary dysfunction
Deficiency states
Folate
Soluble B vitamins
Protein
Caloric
Unknown
vinyl chloride can be leached from membranes,
dialyzer shells, or blood lines [42] and have been
suggested as causes of cardiotoxicity [43] and nec-
rotizing dermatitis [44]. Considering the long-term
and massive exposure to synthetic dialysis materi-
als, a significant toxic effect has yet to be con-
vincingly documented; however, concern about
toxicity persists.
The precipitous drop in the leukocyte count dur-
ing hemodialysis is thought to result from activation
of the complement system during exposure of blood
to dialysis membranes. Leukocyte accumulation in
the pulmonary vasculature has been held respon-
sible for the pulmonary hypertension and hypox-
emia that occur in some patients [45]. A fall in Pa02
also might be related to hypoventilation induced by
the hypocapnia that results from a loss of carbon
dioxide during dialysis [46]. Whatever the cause,
oxygen should be administered during dialysis to
acutely ill patients whose clinical course might be
compromised by mild hypoxemia.
The need to replace folate and B vitamins lost
across the dialyzing membrane has been recognized
for many years. Amino acid loss also can be consid-
erable, and negative nitrogen balance can result if
protein intake is inadequate in the patient on main-
tenance dialysis [47]. Carbohydrate-free dialysate,
used in some units to reduce bacterial con-
tamination, can lead to a loss of calories, which in
turn can stimulate gluconeogenesis [48]. Other defi-
ciency syndromes already might exist in an unrec-
ognized form, and still others might be induced
when membranes with enhanced clearance and ul-
trafiltration capacities become widely employed.
Persistent uremia
It is likely that some complications of uremia per-
sist simply because of the inadequacy of current
dialysis therapy. Table 3 lists some of these Se-
quelae. Clearly, dialysis is not a total replacement
for renal function. Determination of the adequacy
of dialysis is a highly personalized judgment that de-
pends on a combination of clinical and chemical
findings. Measurement of BUN, serum creatinine,
nerve conduction velocity, or any isolated test can-
not determine proper treatment. Patient non-
compliance often undermines adequate treatment,
but recirculation, inadequate access, and failure to
increase the dialysis regimen in the patient with an
increased catabolic rate are other causes for failure
of therapy. Institution of current optimal therapy
can lead to resolution or improvement of most of
the problems listed in Table 3.
Variable degrees of anemia persist in most pa-
tients undergoing maintenance dialysis [49-5 1]. Al-
though this normochromic, normocytic anemia pri-
marily results from decreased erythropoiesis, other
factors including endogenous hemolysis, low-grade
blood loss, iron deficiency, and folate deficiency al-
so might contribute. Anemia is probably the prin-
ciple cause of the fatigue and lethargy frequently
experienced by these patients. The major hazard,
however, is accentuation of cardiovascular or cere-
Table 3. Possible complications of persistent uremia
Anemia
Infection
Pericarditis
Atherosclerotic cardiovascular disease
Secondary hyperparathyroidism
(metabolic bone disease, vascular and visceral calcification)
Encephalopathies
Uremic encephalopathy
Disequilibrium
'Dialysis dementia"
Subdural hematoma
Chemical abnormalities
Hyperlipidemia
Acidosis
Hyperuricemia
Hypermagnesemia
Hyperamylasemia
Azotemia
Peripheral neuropathy
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brovascular symptoms. A sustained high cardiac
output can contribute to the development of cardio-
vascular disease. Given the adverse consequences
of sustained and severe anemia, and the recent find-
ing that blood transfusions appear to be beneficial
rather than detrimental to patients undergoing renal
transplantation [52], we transfuse packed red blood
cells liberally in any patient at risk who has sympto-
matic anemia. Unfortunately, blood transfusions
have untoward consequences, including an in-
creased incidence of HBsAg hepatitis, but red cells
properly screened for HBsAg and prepared by
washing might reduce this risk. Increased iron
stores also have been demonstrated in patients on
chronic dialysis, but morbidity and mortality re-
lated to hemochromatosis have not yet been docu-
mented.
Uremic patients have compromised immune sys-
tems, and an increased frequency of infection has
been reported [53]. Although hemodialysis tends to
correct this immune deficiency, dialysis patients
still seem to have an increased incidence of infec-
tion. For instance, patients with acute renal failure
are particularly prone to septicemia, which is the
most common cause of death in this group [30, 54].
The immune mechanisms might be depressed in pa-
tients with renal failure for a number of other rea-
sons as well. Diverticulosis occurs commonly in
chronic dialysis patients, especially those with
polycystic kidney disease, and often is complicated
by diverticulitis. In our program, these complica-
tions have led to an increase in intraabdominal in-
fections. The high incidence of urinary tract abnor-
malities in these patients leads to an increased rate
of urinary tract infection. Patients being dialyzed af-
ter renal transplantation also contract more infec-
tions, which likely are related to immuno-
suppressive therapy and not to uremia or dialysis.
This association should prompt early reduction or
cessation of immunosuppressive therapy in patients
destined to return to chronic dialysis. Hemodialysis
patients also have an increased incidence of ele-
vated cytomegalovirus titers [55], and CMV infec-
tion probably causes pericarditis. Non-A, non-B
hepatitis and fevers of unknown origin" occur
commonly in these patients. When dialysis patients
develop type-B hepatitis, symptoms of liver in-
volvement are typically lacking and the only mani-
festation is antigenemia. Although prevalence rates
as high as 50% have been reported in some dialysis
units, the rate of antigenemia in many programs is
less than 5% [56]. The incidence of chronic hepatitis
and cirrhosis seems low in dialysis patients, but
Prison, Alexandre, and van Ypersele suggested that
cirrhosis and hepatic failure occur at a higher rate in
HBsAg-positive patients who undergo renal trans-
plantation than in HBsAg-negative patients [57]. Of
course, exposure of blood from patients with chron-
ic antigenemia to nurses, physicians, and other pa-
tients poses a major problem.
Pericarditis occurs at two different periods in pa-
tients with kidney failure. First, it often occurs just
prior to, or soon after, the induction of dialysis. In
contrast to what happened to the patient presented,
the pericarditis usually disappears without sequelae
in patients who are dialyzed adequately. Second,
pericarditis can occur in patients who are dialyzed
chronically. In this setting, it can result from viral
infection or an underlying systemic disease. Re-
cently, Gelfand et al reported an increased in-
cidence of pericardial effusion in uremic patients
being treated with minoxidil [58]. This drug might
have contributed to the effusion in the patient pre-
sented today. Pericarditis occurs most often in
chronic dialysis patients concurrently with stress
such as surgery, trauma, or infection. These pa-
tients, who are hypercatabolic, can manifest a "rel-
ative" uremia that results in pericarditis if the dial-
ysis regimen is not increased. Some clinicians re-
duce the frequency and duration of dialysis
treatments if a concurrent illness develops; I be-
lieve that one should not reduce the dialysis regi-
men but should increase the duration and frequency
of treatment. For the patient with a pericardial fric-
tion rub, peritoneal dialysis can be considered. In
my experience, however, hemodialysis has the ad-
vantage of increasing clearance, and it can be con-
tinued safely if anticoagulation is modified by re-
duction of the heparin dose through infusion, frac-
tional dosage, or the use of carefully controlled
regional heparinization. Pericardial effusion will de-
velop, nonetheless, in a small number of patients
but usually resolves with conservative therapy [59].
In the rare patient who develops cardiac tampo-
nade, we have performed pericardiocentesis utiliz-
ing intrapericardial air infusion (Fig. 1). The proce-
dure is performed by an experienced thoracic sur-
geon and may be repeated as many as three times.
The quantity of air infused is approximately three-
fourths the volume of fluid removed. To ensure that
air is injected into the pericardial sac, simultaneous
peripheral and pericardial hematocrits are deter-
mined, and the fluid removed is observed for ab-
sence of clotting. If location of the catheter is still
not obvious, a small amount of Decholin® is injected
through the catheter, and the patient immediately ex-
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Fig. 1. Chest radiograph showing intrapericardial air injected aj
ter pericardiocentesis.
periences a sweet taste if the catheter tip is in an
atrial or ventricular chamber. Administration of a
non-absorbable steroid intrapericardially [60] and
oral indomethacin [61] have been reported as benefi-
cial and are sometimes used in conjunction with air
instillation. Early pericardiectomy has been advo-
cated because it produces little mortality [62, 63].
However, pericardiocentesis is a much less in-
vasive procedure that offers considerably less mor-
bidity. Over the past 10 years, in our large dialysis
population, intrapericardial air infusion has avoided
thoracotomy and led to resolution of effusion and
tamponade without mortality or significant morbidi-
ty [64].
Some researchers have reported an acceleration
of atherosclerotic cardiovascular disease in uremic
patients on dialysis [65], but one recent study ar-
gues that atherosclerosis is not accelerated in this
population [66]. Failure to define the population un-
der consideration might explain the divergent re-
sults. If one considers entire dialysis populations,
including patients of all ages and those with a long
history of hypertension, then the incidence of ath-
erosclerotic disease is, in fact, increased [3]. If one
examines only young dialysis patients who have no
history of hypertension or other risk factors, no in-
crease in the incidence of atherosclerotic coronary
artery disease is apparent. Longer follow-up is nec-
essary to determine whether dialysis or "partially"
treated uremia are factors in the pathogenesis of
early atherosclerotic disease.
The literature on secondary hyperparathyroidism
in patients on maintenance dialysis is extensive,
and many approaches to prevention and treatment
are described elsewhere. Hyperparathyroidism
does not respond to hemodialysis alone. Diet and
aluminum-containing antacids should be used to re-
duce the serum phosphorus level. Vitamin D ana-
logues can be administered to maintain normal vita-
min D metabolism and calcium absorption which,
with dialysate calcium of 3.25 to 4.0 mEq/liter, will
maintain modestly elevated serum calcium concen-
trations in the hope of preventing or reversing sec-
ondary hyperparathyroidism. In the patient with far
advanced hyperparathyroidism, subtotal para-
thyroidectomy is sometimes necessary [67]. In pa-
tients not treated appropriately, the end results can
include severe proximal myopathy; severe bone
disease with pathologic fracture and pain; and sub-
cutaneous, joint, visceral, and vascular calcification
[68—73].
Several types of encephalopathy can occur in pa-
tients undergoing chronic dialysis [74]. Uremic en-
cephalopathy is common in patients with advanced
renal insufficiency, and mild forms can appear in in-
adequately dialyzed patients. A severe encephalo-
pathy consisting of myoclonic jerking, speech im-
pairment, dementia, and status epilepticus leading
to death has been recognized in long-term dialysis
patients [75]. The cause of this so-called dialysis
dementia" is unknown. Some researchers have sug-
gested that orally administered alumimun gels cause
the syndrome [76], but the sporadic nature of the
disorder and its presence in only small numbers of
patients taking oral aluminum suggest that some
other factor might contribute to its pathogenesis.
Others have indicated that the syndrome is related
to aluminum in water used for dialysis [77]. One
must distinguish the syndrome from atherosclerotic
cerebral vascular disease in the diabetic or elderly
patient. Dementia or unexplained neurologic find-
ings in any patient on hemodialysis should suggest
to the physician the possibility of subdural hemato-
ma [78].
Many chemical abnormalities can persist in pa-
tients on chronic dialysis, including hyperlipidemia,
mild acidosis, hyperuricemia, hypermagnesemia,
hyperamylasemia, and elevated BUN and serum
creatinine levels. The importance of these findings
is unknown. Hypertriglyceridemia and decreased
high-density lipoprotein levels might contribute to
premature atherosclerotic disease; hyperuricemia
might provoke gouty arthritis; and chronic acidosis
probably accentuates metabolic bone disease. Al-
p
t
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though high levels of BUN and serum creatinine
usually are associated with symptoms in uremic pa-
tients who have not undergone dialysis, elevated
values occur in chronic dialysis patients and are not
associated with any obvious clinical problems. The
BUN and serum creatinine can be quite high in pa-
tients with a large body mass, increased tissue ca-
tabolism, or high protein intake. A change in BUN
and serum creatinine levels in such patients is a
more important clue to an underlying problem.
Other problems, most of undetermined cause,
continue to plague patients on chronic dialysis. Pru-
ntis is common and often is severe and unrelenting.
Several therapies have been recommended, al-
though none seems very effective over the long
term. Ultraviolet light therapy is of short-term ben-
efit [79]. Patients, particularly the elderly, frequent-
ly complain of insomnia and fatique. The psychiat-
ric, emotional, and social problems that occur in
dialysis patients are too extensive to be discussed
here but are major complications in this population.
Finally, many serious complications result from the
use of inappropriate drugs and dosage levels in dial-
ysis patients. The physician must have an exact
knowledge of the pharmacodynamics of each drug
used in a patient with renal failure.
Hemodialysis is often lifesaving in patients with
renal failure, but it has many potential side effects,
some of which are lethal. Patients on hemodialysis
should be monitored vigilantly, and their treatment
should be modified to minimize the occurrence of
complications. In any patient being considered for
long-term therapy with hemodialysis, the potential
risks and benefits of this complex treatment should
be weighed carefully before therapy is initiated.
Questions and answers
DR. JOHN T. HARRINGTON: Dr. Lazarus, thank
you very much for an encyclopedic review of the
complications of dialysis, many of which this pa-
tient experienced. One of his major problems was
pericarditis which, because it occurred soon after
the initiation of dialysis, was probably due to ure-
mia, not lupus. It seems to me, however, that some
patients develop pericarditis months after dialysis
has begun and when they are apparently "well dia-
lyzed." What is the cause of pericarditis in this
small group of patients?
DR. LAZARUS: The term "well dialyzed" is rela-
tive. There are many instances in which stable dia-
lyzed patients develop increased catabolism sec-
ondary to other illness or surgery and then become
relatively uremic. I believe that this phenomenon is
probably the most common cause for pericarditis in
the patient receiving maintenance dialysis. Occult
causes of "under dialysis" also might be due to re-
circulation or inadequate blood flow from a poorly
functioning shunt or fistula. The most common
cause for pericarditis in a truly well-dialyzed patient
probably is viral infection.
DR. JEROME P. KASSIRER: How many long- and
short-term complications develop in patients you
would consider adequately dialyzed? That is, what
fraction of well-dialyzed patients remain free of
complications?
DR. LAZARUS: Your question is difficult to an-
swer with an exact percentage. Certainly, the pa-
tient's age and systemic disease are important fac-
tors in the development of complications. The most
common complications, as I mentioned, are related
to shunt and fistula difficulties. Continuing hyper-
tension, progressive secondary hyperparathyroid-
ism, and persisting anemia also are common and
complicate the older patient's course. Significant
mechanical complications should be very rare. In
relatively healthy young people on hemodialysis, I
find the incidence of complications quite low, but
again, I cannot give you an exact percentage. Many
of these younger patients live comfortably for many
years. The complication rate in the young patient is
sufficiently high, however, that transplantation
should be seriously considered as a means of restor-
ing normal renal function. Of course, one also must
consider complications from that therapy as well.
DR. ROBERT RUBIN (Chief of Nephrologv, Lernu-
ci Shattuck Hospital, Boston, Mass.): Dr. Lazarus,
you noted that cytomegalovirus infection is fairly
common and that it might cause pericarditis in
many of these patients. Have you examined CMV
antibody levels in these patients?
DR. LAZARUS: Pericarditis occurring in stable
dialysis patients actually is not common. In patients
whose pericarditis is not due to the causes men-
tioned above, we have assumed the pathogenesis to
be cytomegalovirus because of a lack of another
cause and the clinical presentation. Many chronic
dialysis patients have elevated CMV titers prior to
an episode of pericarditis; therefore, it is necessary
to demonstrate a change in titer. We have seen a
significant elevation in titer in three patients with
otherwise unexplained pericarditis.
DR. RUBIN: How do you evaluate patients who
develop hypotension during hemodialysis?
DR. LAZARUS: A number of things can cause
hypotension in patients during hemodialysis I think
the most common cause is removal of vascular vol-
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ume faster than the patient's vascular system al-
lows. Primary considerations influencing fluid re-
moval are the size of the dialyzer and the rate of
ultrafiltration. Contributing factors include a change
in plasma osmolality, accumulation of acetate, and
underlying autonomic neuropathy. It has been sug-
gested that hypokalemia might play a role in hypo-
tension. However, unless an arrhythmia is induced,
I doubt its contribution. An underlying reduction in
cardiac reserve is probably the major contributing
cause. As I mentioned earlier, the use of anti-
hypertensive medications accentuates hypotension
during dialysis. Whether hormonal abnormalities,
such as the absence or removal of dopamine beta-
hydroxylase, catecholamines, or prostaglandins, af-
fect hypotension during dialysis remains specula-
tive at this time. Initially, I evaluate the appropri-
ateness of volume reduction, and repair the volume
deficit if necessary. This approach often resolves
the problem. Because cardiac status is very fragile
in some patients, dialysis using a low blood-flow
rate and gentle ultrafiltration must be employed.
Hyperosmolar agents such as mannitol, dextrose,
and glycerol have been advocated by some to re-
duce hypotension. We have used dopamine or
metaraminol (Aramine®) during ultrafiltration in the
fluid-overloaded patient who also has hypotension.
One can decrease extracellular volume with this
manipulation, but as dialysis is stopped and the
pressor agent is discontinued, the patient can again
become hypotensive.
DR. WILLiAM B. SCHWARTZ (Professor of Medi-
cine, Tufts University School of Medicine, Boston,
Mass.): Could you comment further about the ace-
tate problem and the problem of bicarbonate deple-
tion in dialysis patients?
DR. LAZARUS: As I mentioned earlier, it was
demonstrated a number of years ago that acetate
can accumulate in a small percentage of patients on
dialysis [17, 18]. Patients with hepatic disease seem
to be particularly prone to this problem, but the ab-
normality also occurs in patients who have no ap-
parent hepatic insufficiency. Several investigators
have demonstrated a transient decrease in plasma
bicarbonate concentration during and just after he-
modialysis. Sargent and Gotch in an elaborate study
demonstrated that body bicarbonate stores can be
depleted after long periods of acetate hemodialysis
[161. Although the exact cause of acetate accumula-
tion has not been well studied, acetate excess must
result from (1) a rate of acetate presentation that
exceeds the metabolic clearance; (2) a reduction in
acetate delivery to active metabolic sites because of
circulatory insufficiency; or (3) a defect in acetate
metabolism. I am not aware of studies that have in-
vestigated further the exact mechanism of acetate
metabolism in hemodialyzed uremic patients.
DR. HARRINGTON: The plasma bicarbonate con-
centration is 15 to 17 mEq/liter in most patients dia-
lyzed against acetate, whereas patients who have
been dialyzed against bicarbonate have higher
plasma bicarbonate concentrations. I believe the
"defect" in the acetate metabolism is best defined
quantitatively. Twenty-four hours after acetate dial-
ysis, the acetate level is not elevated; acetate accu-
mulates only during the dialysis itself. Tolchin et al
demonstrated that accumulation of acetate levels is
most marked in patients being dialyzed with large-
surface-area dialyzers (2.5 m2); serum acetate levels
rose to 5 to 10 mM/liter in these patients. It is of
interest, however, that none of these patients devel-
oped significant hypotension [14].
DR. JORDAN J. COHEN: You emphasized that per-
sistent hypervolemia is hard to detect in the dialysis
patient and alluded to the frequently observed di-
uresis after successful transplantation. Has post-
transplant diuresis been studied systematically to
assess how much extra fluid is typically present in
an apparently well-dialyzed patient?
DR. LAZARUS: I am not aware of a study of extra-
cellular or vascular volume status before and after
successful transplantation. I think most nephrolo-
gists appreciate this phenomenon, however.
DR. NICOLAOS MADIAS (Renal Service,
NEMCH): As you know, several people believe
that we wait too long before starting dialysis. Some
European nephrologists, for example, suggest that
we probably should start dialysis when the glomeru-
lar filtration rate reaches 15 to 20 cc/minute. They
reason that waiting until the GFR reaches very low
levels is unwise because of the multiple physiologic
derangements that result. In view of the complica-
tions you have just reviewed, when do you think
dialysis should be begun?
DR. LAZARUS: Timing of the initiation of dialysis
is a difficult issue. I do not believe there is an abso-
lute level of renal insufficiency that determines
when dialysis should be started. Clearly, if one
waits until the patient has neuropathy, pericarditis,
severe central nervous system disease, or other se-
rious complications of uremia, one has waited too
long. I believe that dialyzing patients with a clear-
ance of 15 to 20 cc/minute is not justified, however,
because the risk at this level outweighs the benefits.
Patients with slowly progressive renal insufficiency
should be monitored regularly, and dialysis should
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be started when the patient experiences a signifi-
cant change in the quality of life. If the patient is
symptomatic and cannot function normally, and if
the problem is not correctable by conservative mea-
sures, then hemodialysis should be started regard-
less of the serum creatinine and BUN levels. On the
other hand, many of us treat patients whose serum
creatinine levels are as high as 18 to 20 mg/dl and
whose urea nitrogen levels approach 200 mg/dl yet
who have few physical findings or symptoms. With
careful follow-up, these patients can be managed
conservatively. It is interesting that diabetics com-
monly become symptomatic with relatively low
BUN or serum creatinine levels.
Early transplantation is also a reasonable thera-
peutic consideration prior to the final stage of
chronic renal insufficiency. While I was at the Chil-
drens Hospital Medical Center, we transplanted
kidneys in children early in the course of renal in-
sufficiency in an effort to obtain normal renal func-
tion and achieve improved growth [80]. In the older
patient with a well-matched kidney from a willing
sibling, early transplantation again is worth consid-
ering.
DR. COHEN: You emphasized the frequency of
CMV infections. Is there any prospect of immuniza-
tion against this virus?
DR. LAZARUS: I know of no efforts to develop im-
munization against cytomegalovirus. In the dialysis
patient, the problem might not be sufficient to war-
rant its routine use. The problem of CMV infection
in transplant patients, however, is another issue;
immunization might be important in that situation.
DR. SANG CHO (Chief, Transplant Surgery,
NEMCH): Control studies of interferon are being
carried out at this time by the renal transplantation
group at the Massachusetts General Hospital [81].
The data suggest that interferon might reduce both
the incidence and intensity of infection. It was my
impression that CMV immunization would require a
live, attenuated virus, which would impose a risk on
transplant and dialysis patients, who are immuno-
suppressed and might not be able to tolerate a live
virus vaccine.
DR. COHEN: At one time nerve conduction veloc-
ity tests were popular as a means of assessing the
adequacy of dialysis. Do you find these studies still
valuable?
DR. LAZARUS: The motor nerve conduction ve-
locity study is a delicate test that must be performed
appropriately, and room temperature, proper posi-
tion of patients, and proper technique by the exam-
iner must be taken into account. The test can have
wide variability in the same patient, particularly a
uremic patient who has neuropathy. Because nerve
conduction velocity in uremic patients often is pro-
longed, isolated studies in dialysis patients are not
helpful [82], and the clinical evaluation often can be
just as rewarding as the nerve conduction velocity
test. A trend in nerve conduction velocity over a
long period, however, sometimes provides valuable
information. We currently use serial nerve con-
duction velocity studies as a tool in evaluating the
adequacy of dialysis. Neurobehavioralists are now
evaluating psychologic tests that they believe might
prove more valuable in assessing the adequacy of
dialysis [83].
DR. COHEN: You emphasized the problem of
bleeding in dialysis patients due to their require-
ment for anticoagulation. Are any new strategies
being developed that might reduce that complica-
tion?
DR. LAZARUS: Yes, several drugs are being eval-
uated. Prostacyclin and ticlopidine, two agents that
affect platelet adhesiveness, are being evaluated. In
trying to prevent clotting without using systemic
anticoagulation, some researchers have tried to at-
tach heparin to dialysis membranes, but these at-
tempts have not been successful, primarily because
heparin is released from the membrane. At present,
systemic anticoagulation with heparin remains a ne-
cessity for hemodialysis.
DR. MARTIN GELMAN (Renal Division, St. Eliza-
beth's Hospital, Boston, Mass.): I would like to re-
turn to the pericarditis issue. Your data supporting
nonoperative intervention in patients with pen-
carditis are very impressive. Other researchers,
such as those in Minnesota, believe that surgery is
virtually always necessary [60]. Do you think air in-
stillation makes the difference?
DR. LAZARUS: I believe so. A number of papers
in the last five years have advocated early pericar-
diectomy as the procedure of choice for pericardial
effusion because penicardiectomy is a safe opera-
tion [62, 63]. This might be true; however, just be-
cause an operation is safe does not make it neces-
sary. We have had no difficulties with pen-
cardiocentesis, primarily because the procedure is
performed in our institution by an experienced tho-
racic surgeon. The use of echocardiography has
been valuable in this regard. Intrapericardial air al-
lows a more thorough drainage of fluid, gives imme-
diate pain relief, and prevents reaccumulation of
significant fluid. The use of nonabsorbable steroids
in the pericardium has been reported by the Minne-
sota group as being effective also [60]. We have not
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had to resort to thoracotomy and pericardiectomy
in the treatment of pericardial tamponade.
DR. HARRINGTON: Have you had any problems
with the late sequelae of pericardial effusion such as
constrictive pericarditis?
DR. LAZARUS: During the past 12 years, 2 of our
patients have developed constrictive pericarditis.
One was a home-dialysis patient who developed the
syndrome 6 to 8 weeks after having had pericarditis
without pericardial effusion. The other was an el-
derly patient whose constrictive pericarditis oc-
curred approximately 2 years after a pericardial ef-
fusion that cleared spontaneously. Neither of these
patients had required pericardiocentesis earlier.
The incidence of constrictive pericarditis is quite
low. I do not believe that the possibility of con-
strictive pericarditis warrants early pericardi-
ectomy, as the incidence is low and the procedure
can be done when constriction is demonstrated.
DR. GELMAN: What is the overall incidence of ef-
fusion in your patients? Are pericardial effusions re-
current in this group?
DR. LAZARUS: We screened a population of pa-
tients on maintenance dialysis who had no symp-
toms, and we found an incidence of anterior pen-
cardial effusion of approximately 20% [841. Other
groups have performed serial studies indicating that
pericardial fluid accumulation is evanescent [85].
Reprint requ'sts to Dr. J. Michael Lazarus, Nephrology Divi-
sion, Peter Bent Brigham Hospital, 721 Huntington Avenue,
Boston, Massachusetts 02115, USA
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